Riabni
Active substance: rituximab
INJECTION, SOLUTION · RITUXIMAB 100 mg/10mL
United StatesActive
Marketing holder: Amgen, Inc
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 3
- RITUXIMAB · 100 mg/10mL
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| RU 15 |
|
| EU 10 |
|
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-2e5b-7385-bac1-a7a60dcbc99a,01a120c3-5f62-77b6-85cb-2c4a65d1bf3d,01a120c3-5f6c-7694-a855-64734e32d1b3,01a120c3-7d80-7d8b-a981-ac94cf76b979,01a120c3-e93b-7471-beec-65248e0ffeaf;count=12 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a1208d-6a24-7d42-b69d-bc0de62bed96,01a1208e-5ef8-76b6-96fe-0484f6611855,01a1208e-7a1b-70e9-9505-7b797448d519,01a12091-b65a-7637-ad89-32ff5711dc48,01a12091-e0aa-77d9-ad0a-d0a8bafee2e0;count=8 · valid from 2026-10-09 · verified 2026-10-09
- Registration number
- 55513-224
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- INTRAVENOUS
- product · openFDA NDC · 55513-224 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 55513-224 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 55513-224 · Verified 2026-10-09 · open in source